Dermata Therapeutics, Inc. (NASDAQ:DRMA) Financings
Financings
| Raise | Date |
|---|---|
| Private placement of shares of common stock (or pre-funded warrants) with series E and series F warrants Announced: about US$3.4M · US$1.46 a share · Warrants at US$1.46 Insiders: Company insiders, including the CEO, CFO and a member of management, are participating at $1.47 per share and accompanying warrants, with warrant exercise price of $1.47 Use of proceeds: General corporate purposes incl. consumer research, launch of direct-to-consumer product, acquisitions, licensing and working capital | Aug 17, 2026 |
| Private placement of shares of common stock (or pre-funded warrants) with series C and series D warrants Closed: US$4.1M raised · US$2.04 a share · Warrants at US$2.04 · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Insiders: Company insiders, including the CEO, CFO and certain members of management, participated in the offering Use of proceeds: General corporate purposes, including consumer research, launch of OTC acne kit, acquisitions, licensing and working capital | Dec 29, 2025 |
| Warrant exercise of common stock upon exercise of existing warrants Announced: about US$6.2M · US$1.284 a share · Warrants at US$1.284 · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. Use of proceeds: General corporate purposes, including research, clinical trials, technology development, licensing, acquisitions and working capital | Mar 28, 2025 |
| Private placement of shares of common stock (or pre-funded warrants) and accompanying warrants Closed: US$2.55M raised · US$1.27 a share · Warrants at US$1.27 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Insiders: Company insiders, including the CEO, CFO and certain board members, participated at the same price as other investors Use of proceeds: General corporate purposes, including research, pre-clinical studies, clinical trials, licensing and working capital | Jan 23, 2025 |